Palbociclib is a drug for the treatment of ER-positive and HER2-negative breast cancer developed by Pfizer. It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6.
It was reviewed and approved under the Food and Drug Administration`s (FDA) accelerated Priority Review and Breakthrough Therapy designation programs on February 3, 2015 as a treatment (in combination with letrozole) for patients with estrogen receptor positive advanced breast cancer.
We produce a series of complete intermediates for Palbociclib, intermediate I (CAS No. 571188-59-5), intermediate II (CAS No. 1013916-37-4) and intermediate III (CAS No. 1016636-76-2) etc.
All of our products are with stable production and strict quality control, making sure your experience with Sunshine Biotech is always enriching, satisfying and fulfilling.
Contact Now
